Figure 5

Orthotopically implanted DU-145 human prostate carcinoma cells. At day 65 (i.e., 26 days after the last treatment with selinexor (KPT-330) at the dose of 4 mg/kg, and 7 days after last treatment with selinexor at the dose of 10 mg/kg) mice were sacrificed for evaluating antitumor activity of the drug. (A) table summarized the pharmacological effects of selinexor including Toxicity, Body weight Loss (BWL), tumor mass weight, tumor mass reduction and macroscopic dissemination in the peritoneal surface and diaphragm. (B) single tumor mass weight in different treatment groups. (C) percentage of mice with macroscopically evident dissemination.